Menin inhibitors for acute myeloid leukemia: latest updates from the 2023 ASH Annual Meeting
Abstract Recent developments in menin inhibitors for relapsed or refractory acute myeloid leukemia (AML) were highlighted at the 2023 ASH Annual Meeting. Notably, revumenib showed promising efficacy, achieving a 100% ORR when combined with decitabine/cedazuridine and venetoclax. These findings under...
Na minha lista:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMC
2024-07-01
|
| coleção: | Journal of Hematology & Oncology |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1186/s13045-024-01573-2 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|